RxDoctor Payments Data

Frank Civitarese, DO

Family Medicine · Carnegie, PANPI 1811961055

Payments from drug & device makers

$421in general payments, 2019–2025

Across 24 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$124
  • AbbVie$105
  • Merck$52
  • Novo Nordisk$39
  • Pfizer$31
  • Lilly USA, LLC$23
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$369100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$124
AbbVie(2 entities)5$105
Merck3$52
Novo Nordisk2$39
Pfizer2$31
Lilly USA, LLC1$23
W. L. Gore & Associates, Inc.1$17
Abbott1$17
Metuchen Pharmaceuticals1$13

How this compares

$421 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$108,864
Medicare patients
312
Services billed
2,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$78,458
TrulicityDulaglutide56$75,829
OzempicSemaglutide29$42,402
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$38,858
XareltoRivaroxaban32$30,028
JardianceEmpagliflozin19$19,582
AbrysvoRsv Vacc, Pref A And Pref B/Pf36$11,569
MyrbetriqMirabegron16$11,535
ShingrixVaricella-Zoster Ge/As01b/Pf36$7,927
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,057
Atorvastatin Calcium417$5,201
Potassium Chloride100$3,956
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf56$3,945
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro13$3,078
BreynaBudesonide/Formoterol Fumarate11$2,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$31$90,027105 claims
Lilly USA, LLCTrulicity$23$75,82956 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$124$52,842103 claims
Novo NordiskOzempic$39$42,40229 claims
AbbVieSynthroid$105$1,11130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Carnegie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →